Perspective Therapeutics (NYSE:CATX) Receives "Outperform" Rating from Wedbush

Perspective Therapeutics (NYSE:CATX - Get Free Report)'s stock had its "outperform" rating restated by stock analysts at Wedbush in a research note issued on Friday,RTT News reports. They currently have a $11.00 target price on the stock. Wedbush's target price would suggest a potential upside of 174.31% from the company's current price.

Other equities research analysts have also recently issued research reports about the stock. Bank of America cut shares of Perspective Therapeutics from a "buy" rating to a "neutral" rating and dropped their price objective for the stock from $24.00 to $5.00 in a research note on Monday, November 25th. Oppenheimer dropped their price target on shares of Perspective Therapeutics from $22.00 to $16.00 and set an "outperform" rating on the stock in a research report on Friday, November 22nd. UBS Group started coverage on shares of Perspective Therapeutics in a research note on Thursday, October 24th. They set a "buy" rating and a $20.00 target price on the stock. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $16.00 price target on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $15.14.

Perspective Therapeutics Trading Up 10.5 %

Perspective Therapeutics stock traded up $0.38 during mid-day trading on Friday, reaching $4.01. 1,730,130 shares of the company traded hands, compared to its average volume of 1,172,306. The firm's fifty day moving average is $3.68 and its two-hundred day moving average is $9.76. Perspective Therapeutics has a fifty-two week low of $2.70 and a fifty-two week high of $19.05.

Perspective Therapeutics (NYSE:CATX - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, meeting the consensus estimate of ($0.21). Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. The business had revenue of $0.37 million for the quarter. Analysts predict that Perspective Therapeutics will post -0.88 EPS for the current year.

Insider Transactions at Perspective Therapeutics

In related news, CEO Johan M. Spoor purchased 14,500 shares of Perspective Therapeutics stock in a transaction that occurred on Monday, November 25th. The stock was purchased at an average cost of $3.78 per share, with a total value of $54,810.00. Following the completion of the transaction, the chief executive officer now directly owns 152,072 shares in the company, valued at approximately $574,832.16. The trade was a 10.54 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Heidi Henson acquired 25,975 shares of the firm's stock in a transaction on Wednesday, December 4th. The stock was bought at an average price of $3.85 per share, with a total value of $100,003.75. Following the purchase, the director now directly owns 25,975 shares of the company's stock, valued at $100,003.75. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders bought 67,570 shares of company stock valued at $256,789. Insiders own 3.52% of the company's stock.

Institutional Investors Weigh In On Perspective Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. nVerses Capital LLC purchased a new position in Perspective Therapeutics during the third quarter worth about $57,000. Trueblood Wealth Management LLC lifted its stake in shares of Perspective Therapeutics by 37.0% in the fourth quarter. Trueblood Wealth Management LLC now owns 22,236 shares of the company's stock valued at $71,000 after purchasing an additional 6,000 shares during the period. Koa Wealth Management LLC purchased a new position in Perspective Therapeutics in the fourth quarter valued at about $83,000. SG Americas Securities LLC lifted its position in shares of Perspective Therapeutics by 41.3% during the 4th quarter. SG Americas Securities LLC now owns 26,088 shares of the company's stock valued at $83,000 after acquiring an additional 7,627 shares during the period. Finally, US Bancorp DE boosted its stake in shares of Perspective Therapeutics by 142.7% during the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company's stock worth $88,000 after acquiring an additional 3,866 shares in the last quarter. 54.66% of the stock is owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.